Health industry: what autonomy for Europe?

Serge BERNASCONI

CEO
MEDTECH EUROPE

Belgium

Currently CEO MedTech Europe
Medtech Europe is the European association which represents the interest of the MedTech Industry in Brussels (Staff of 45 people - dealing with Brussels – EU institutions and Health stakeholders) and in Europe through the network of over 45 National trade Associations all members of MedTech Europe. MedTech Europe is composed of Medical device companies, IVD companies, National Associations and others which individual associations merged in December 2016.

Medtronic (2007 – 2012) – Medical Devices
President Medtronic France and Vice President Medtronic Europe – (5 years) (Paris, France)
President of APIDIM (trade association of US MedTech Companies in France) and Vice-president / treasurer of SNITEM (French trade Association of MedTech).

Schering Plough (1998 – 2007) - Pharma
Vice President, Middle East Africa – Schering Plough (Pharma) (5 Years) - (Dubai, UAE)
8 affiliates reported into the function.
Director, BU Respiratory, Schering -Plough France – 4 years (Exec. Committee)

Johnson & Johnson – 17 years (1981 – 1998) - Pharma
Janssen-Cilag – Paris (France) (4 years)
Lead integration of Cilag & Janssen in France, BU Director, Sales Administration & Training Director. (Exec. Committee)
Cilag International – Zurich (Switzerland) (3 years):
International Business Development Director (Derm/Gynecology Franchises)
Ortho Pharmaceuticals – Derm Division – US (11 years):
Sales Rep, Mkt Research, product manager, Regional Sales manager, Marketing Director.

Paul HUDSON

CEO
SANOFI

France

Paul Hudson joined Sanofi, a global biopharmaceutical company, as Chief Executive Officer in September 2019. He has over 25 years of experience driving growth and building strong teams for pharmaceutical companies in the United States, Asia and Europe.
Paul began his career in sales and marketing, ascending to CEO of Novartis Pharmaceuticals before joining Sanofi.
He holds a degree in economics from Manchester Metropolitan University, which awarded him an honorary Doctor of Business Administration for his achievements in the pharma industry. He also holds a diploma in marketing from the Chartered Institute of Marketing in the U.K.

Olivier NATAF

President
Astrazeneca France

France

A scientist by training, graduated in molecular biology from Pierre et Marie Curie University and from the University of Chicago also holds a MS in Pharmaco-Oncology from the École Normale supérieure, and a MS from École Supérieure de Commerce in Paris (ESCP) and a Master from The French Institute for International and Strategic Affairs (IRIS).
Before being appointed President France at the end of 2019, Olivier Nataf headed AstraZeneca's Oncology Business Unit in the United States, where he significantly contributed to developing this market. He also helped establish the collaborations with Merck, Innate Pharma and Daiichi- Sankyo for the entire Group.
In 2020, his commitment led him to join the Board of Directors of the LEEM and to become Chairman of the LEEM Cancer Committee. In addition, he also committed as Vice-President to the think tank Laboratoires Internationaux de Recherche (LIR).
His transversal vision but also his understanding of the patients’ route led him to committing in health innovation by inviting to a public-private collaboration. He contributed to the strong involvement of AstraZeneca to “L’Alliance Digitale Contre le COVID-19”. He is co-Founder of “Coalition Innovation Santé” alongside France Digitale, France Biotech and MedTech in France with the support of AP-HP, Bpifrance, EIT Health.
At the same time, his strong societal convictions led him to engage AstraZeneca as a social and civic actor: by the signature of an unprecedented partnership with L’Ascenceur (a collective of 20 associations working for equal opportunities) to support young people in their education, in their access to labour market, and in all activities for a greater social inclusion; through actions to reducing the company's carbon footprint through better control of the drug's life-cycle or, as part of the AZForest project, to act for reforestation operation in France.